Flu, Nosing out the competition

Mode of delivery as well as ability to both treat and prevent influenza are the factors the vaccine competitors are using to differentiate their products and address a market characterized by increasing public awareness of the flu's impact.

Wyeth chose FluMist because it is likely to be the first intranasal influenza vaccine to reach the market, according to Douglas Petkus, spokesperson for Wyeth-Ayerst Laboratories (Philadelphia, Penn.), of which Wyeth Lederle is a business unit. Wyeth believes this mode of delivery could help it expand the overall use of influenza vaccine...